Clinical trial
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell…
NCT00138086 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00138086 |
|---|---|
| Title | Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma |
| Official title | Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT) |
| Lead sponsor | Lymphoma Study Association, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Zevalin plus BEAM |
| Enrollment | 75 |
| Start date | Mar 1, 2005 |
| Completion | Mar 1, 2009 |
| First posted | Aug 30, 2005 |
| Last update posted | Sep 8, 2006 |
| Countries | Belgium, France, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: